Silencing E3 Ubiqutin ligase ITCH as a potential therapy to enhance chemotherapy efficacy in p53 mutant neuroblastoma cells by Meng, Jinhong et al.
1Scientific RepoRtS |         (2020) 10:1046  | https://doi.org/10.1038/s41598-020-57854-6
www.nature.com/scientificreports
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P53 mutations are responsible for drug-resistance of tumour cells which impacts on the efficacy of 
treatment. Alternative tumour suppressor pathways need to be explored to treat p53- deficient 
tumours. The E3 ubiquitin ligase, ITCH, negatively regulates the tumour suppressor protein TP73, 
providing a therapeutic target to enhance the sensitivity of the tumour cells to the treatment. In 
the present study, two p53-mutant neuroblastoma cell lines were used as in vitro models. Using 
immunostaining, western blot and qPCR methods, we firstly identified that ITCH was expressed on 
p53-mutant neuroblastoma cell lines. Transfection of these cell lines with ITCH siRNA could effectively 
silence the ITCH expression, and result in the stabilization of TP73 protein, which mediated the 
apoptosis of the neuroblastoma cells upon irradiation treatment. Finally, in vivo delivery of the ITCH 
siRNA using nanoparticles to the neuroblastoma xenograft mouse model showed around 15–20% ITCH 
silencing 48 hours after transfection. Our data suggest that ITCH could be silenced both in vitro and in 
vivo using nanoparticles, and silencing of ITCH sensitizes the tumour cells to irradiation treatment. This 
strategy could be further explored to combine the chemotherapy/radiotherapy treatment to enhance 
the therapeutic effects on p53-deficient neuroblastoma.
Neuroblastoma is a childhood malignant tumour accounting for ~13% of all paediatric cancer mortality1. Some 
types of neuroblastoma are prone to developing drug-resistance during the course of treatment2. One of the genes 
responsible for this phenomenon is p533–6, a well-characterized tumour suppressor protein, which binds to vari-
ous transcriptional factors mediating apoptosis of tumour cells7,8. Mutations of p53 lead to compromised tumour 
cell death and eventually the irresponsiveness to the chemotherapy treatment6–8.
Attempts to restore or reactivate the wide-type p53 function for tumour therapy9–14 are under investigation 
but it may be possible to utilize alternative pathways to compensate for the missing p53 function15–17. TP73 is a 
homologous molecule of p53 and shares significant sequence similarity particularly in the DNA binding domain 
(DBD), activation domain (AD) and tetramerization domain (TD)18. TP73 shows tumour suppressive activi-
ties through its ability to bind transcriptional target genes involved in apoptosis. Overexpression of wild type 
TP73 promotes the apoptosis of transformed cells. In addition, p73 mutations are infrequent in human cancers17 
including neuroblastomas19,20, making it an attractive gene to manipulate for therapeutic intervention of the 
p53-null tumours.
TP73 is expressed at low levels in normal tissues, but may be upregulated in some types of tumours21–24 or 
under conditions where p53 is inactivated25. The expression level of p73 protein is regulated by the E3 ubiquitin 
ligase ITCH26 via its ubiquitination pathway. Thus, inhibition of ITCH could elevate p73 expression and enhance 
the chemo-sensitivity of the tumour cells, especially those with defective p5327. In addition to p73, ITCH also 
regulates other tumour suppressor genes such as large tumour suppressor 1 (LATS1)28,29, p6330,31, and RASSF5/
NORE132, providing an attractive therapeutic target for tumour therapy. In this study, we tested the hypothesis 
that modulation of ITCH expression would enhance the sensitivity of the tumour cells to treatment. To do this, 
we used two TP53-null neuroblastoma cell lines as in vitro models, and used siRNA to downregulate ITCH 
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expression. Furthermore, utilizing nanoparticles33,34, we tested the in vivo silencing efficacy of the candidate 
ITCH siRNAs in a neuroblastoma xenograft model.
Our study provides evidence that ITCH can be effectively silenced in neuroblastoma both in vitro and in vivo. 
Silencing of ITCH in vitro stabilizes TP73 protein on neuroblastoma cells and sensitizes the cells to irradiation 
treatment. Our results suggest that this novel strategy is feasible for combining with the conventional chemo-/
radio-therapy to treat the drug-resistant TP53-null neuroblastomas.
Results
Expression of ITCH and TP73 in neuroblastoma cell lines. To determine the optimal in vitro cell 
culture model for this project, we chose two p53 -mutant neuroblastoma cell lines, Kelly and BE2 cells, and per-
formed semi-quantitative RT-PCR, real time qRT-PCR and immunostaining to determine the expression levels 
of ITCH and p73 in these two cell lines.
As shown in Fig. 1, RT-PCR on mRNA extracted from the proliferating Kelly cells and BE2 cells showed that 
both these two cell lines expressed ITCH and TP73. Real-time qRT-PCR suggested that Kelly cells express higher 
levels of ITCH and TP73 than BE2 cells (Fig. 1A). Immunostaining showed that both cell lines also expressed 
ITCH and TP73 protein (Fig. 1B). Therefore, both cell lines could be used for transfections with ITCH siRNA in 
order to knockdown ITCH expression.
Expression of integrin αv, β3 and β5 on neuroblastoma cells. It has been shown that nanoparticles 
containing peptide ME27, which contains an integrin-targeting RGD motif, can be an effective delivery tool for 
in vivo tumour targeting35,36 and we planned to use the same peptide for our in vivo silencing experiment. Thus, it 
was important to establish that the tumour cells expressed integrin receptor proteins to enable the specific target-
ing of the tumour by nanoparticles. Therefore, we examined the expression of the specific ME27 ligands, integrins 
αv, β3 and β5 in neuroblastoma cells by RT-PCR, immunostaining and western blot analysis.
As shown in Fig. 2, we found that both Kelly and BE2 cells expressed integrins αv, β3 and β5 at the mRNA 
level (RT-PCR, Fig. 2a) and protein level (immunostaining, western blot, Fig. 2c,b). This result suggested that 
these neuroblastoma cells can be targeted by the nanoparticles via the interaction between the ME27 peptide and 
integrins.
In vitro silencing of ITCH in neuroblastoma cell lines. Transfection using Lipofectamine 2000 (L2K) reagent. 
To determine ITCH silencing in neuroblastoma cells in vitro, we firstly transfected neuroblastoma cells with 
ITCH siRNA, using L2K as the transfection reagent. To determine the optimal condition of the siRNA transfec-
tion, cells were transfected with either a) ITCH siRNA (6.25 nM to 100 nM) using 2 µl/well L2K, or b) Different 
amounts of L2K (0.5 µl/well, 1 µl/well and 2 µl/well in 24-well plate) with 100 nM ITCH siRNA for 4 hours in 
OptiMEM, and then change into complete medium for a further 72 hours. The ITCH mRNA levels were deter-
mined by qRT-PCR, and cells transfected with irrelevant siRNA were used as the control.
Effects of siRNA concentration on ITCH mRNA knockdown in neuroblastoma cells. In Kelly cells, after trans-
fection, the level of ITCH mRNA was 22 ± 3.6%, 11 ± 6%, 26.5 ± 1%, 22.2 ± 0.3% and 35.3 ± 0.3% in 100 nM, 
50 nM, 25 nM, 12.5 nM and 6.25 nM ITCH siRNA transfected groups, respectively, of that transfected with cor-
responding irrelevant siRNAs (Fig. 3A). Kruskal-Wallis test followed by multiple comparisons suggested that 
there were significant dose-dependent differences between cells transfected with 50 nM and 25 nM, or 50 nM 
and 6.25 nM, or 12.5 nM and 6.25 nM ITCH siRNAs. Cells transfected with 50 nM ITCH siRNA showed the best 
knockdown efficiency. Similarly, in BE2 cells, there were 63.8 ± 7.8%, 26.5 ± 1.8%, 50.3 ± 1.7%, 44.6 ± 2.1% and 
134.5 ± 0.4% ITCH mRNA expression in 100 nM, 50 nM, 25 nM, 12.5 nM and 6.25 nM ITCH siRNA transfected 
Figure 1. Expression of ITCH and TP73 in neuroblastoma cell lines. (A) RT-PCR and the qPCR results of the 
expression in Kelly cells and BE2 cells, (B) immunostaining showing the expression of ITCH and TP73 at the 
protein level, scale bar = 25 µm.
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groups, respectively, in comparison to that transfected with corresponding irrelevant siRNAs. Kruskal-Wallis test 
followed by multiple comparisons suggested there were dose- dependent differences between 50 nM and 6.25 nM 
ITCH siRNA transfected groups (Supplementary Fig. 1). Cells transfected with 50 nM ITCH siRNA showed the 
best knockdown efficiency.
To determine the potential dose-related toxicity of siRNA, we examined the cell viability after transfection of 
different concentrations of siRNA. FACS analysis of PI staining showed that there was no dose-dependent toxic-
ity on Kelly cells (Fig. 3A); while 100 nM siRNA-transfected BE2 cells contained significant more PI + cells than 
non-transfected cells and 6.25 nM siRNA-transfected cells, evidence of toxicity of high dose siRNA on BE2 cells 
(Supplementary Fig. 1).
Effects of amount of L2K on ITCH mRNA knockdown in neuroblastoma cells. In Kelly cells, using 100 nM siRNA, 
15 ± 0.6%, 17 ± 0.6% and 21.2 ± 0.6% ITCH mRNA were detected in cells transfected with 0.5 µl/well, 1 µl/well 
and 2 µl/well L2K, respectively, in comparison to corresponding irrelevant siRNA transfected cells (Fig. 3A). In 
BE2 cells, 4.2 ± 0.7%, 48.4 ± 0.6% and 71.9 ± 0.6% ITCH mRNA was observed in cells transfected with 0.5 µl/well, 
1 µl/well and 2 µl/well L2K, respectively, in comparison to corresponding irrelevant siRNA-transfected cells 
(Supplementary Fig. 1). Cell viability analysis on both cell lines showed that both 0.5 µl/well and 1 µl/well trans-
fected cells contained similar amount of PI + cells to that of control cells, while 2 µl/well transfected cells contained 
significant more PI + cells than non-transfected cells (Fig. 3A and Supplementary Fig. 1). These results suggested 
that the cells transfected with lower amounts of transfection reagent (0.5 µl/well and 1 µl/well) have higher transfec-
tion efficiency, with lower toxicity than cells transfected with a higher amount of reagent (2 µl/well).
Knockdown of ITCH protein in neuroblastoma cells using L2K reagent. Next, we tested the extent of ITCH silenc-
ing at the protein level in neuroblastoma cells, using L2K as transfection reagent. Kelly and BE2 cells were trans-
fected with 50 nM ITCH siRNA/irrelevant siRNA and 0.5 µl/well L2K, and cell lysates were collected 72 hours 
after transfection. As shown in Fig. 3B, the ITCH protein level was 31.6% in ITCH siRNA-transfected Kelly cells 
(Fig. 3B-a), in comparison to non-transfected cells. However, there were no changes in ITCH protein level in 
treated BE2 cells in comparison to irrelevant siRNA-treated cells (Fig. 3B-b).
Based on the western blot results from the Kelly and BE2 cells, we determined that the Kelly cell line was 
more responsive to the ITCH siRNA treatment than the BE2 cell line, in terms of silencing at the protein level. 
Therefore, in the in vivo experiment that followed, we chose to use Kelly cells to establish the xenograft models.
Figure 2. Expression of integrin αv, β3 and β5 in neuroblastoma cells. (a) RT-PCR; (b) western blot and (c) 
immunostaining all showed the presence of these integrin molecules in the neuroblastoma cell lines, Kelly and 
BE2, scale bar = 25 µm.
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Transfection using nanoparticles. We also transfected Kelly cells with nanoparticles containing lipos-
omes formulated with different concentration of polyethylene glycol (PEG)35. Three types of lipids were used as 
following: DOTMA/DOPE, with no PEG; AT-1, containing 1% PEG and GK27, which contains 5% PEG. Kelly 
cells were plated in 24-well plates at a density of 8 × 104 cells/well. On the day of the transfection, cells were trans-
fected with the following formulations: 1) DOTMA/DOPE: ME27: ITCH siRNA; 2) AT-1:ME27: ITCH siRNA 
and 3) GK27:ME27: ITCH siRNA, all at a ratio of 1:4:1. Cells transfected with irrelevant siRNA with correspond-
ing formulations were used as negative controls. Cells transfected with L2K and ITCH siRNA were also included 
as a positive control. The concentration of siRNA used in this experiment was 100 nM. All transfections were 
performed in OptiMEM and 2 time points were compared in this experiment: 4 hours (nanocomplexes left for 
4 hours on cells and then replaced with complete media) and 48 hours after transfection (nanocomplexes left for 
48 hours on cells in complete media).
As shown in Fig. 3C, when the cells were transfected for 4 hours, there was 70% knockdown (29.6 ± 15% ITCH 
mRNA) of ITCH in the DOTMA/DOPE:ME27:ITCH siRNA-transfected group. However, AT-1:ME27:ITCH 
siRNA and GK27:ME27:ITCH siRNA-transfected groups achieved either none (109 ± 21% ITCH mRNA) or 
small amount (around 22% knockdown, 72.8 ± 16.9% ITCH mRNA) of ITCH silencing (Fig. 3C-a). However, 
when the cells were transfected for 48 hours (Fig. 3C-b), which means that the nanoparticles stay in the medium 
throughout the experiment, there was around 42% knockdown (58.4 ± 9.5% of ITCH mRNA) of ITCH in 
DOTMA/DOPE:ME27:ITCH siRNA-transfected group, 37% knockdown (59.5 ± 6.3% ITCH mRNA) in 
Figure 3. Knockdown of ITCH in vitro using LipofectAMINE2000 (L2K) (A,B) or nanoparticles (C).  
(A) qPCR of ITCH mRNA (a and b) of Kelly cells transfected with different concentrations of ITCH siRNA 
(a) or using different amounts of L2K reagent (b). The cell viability in each transfection condition is indicated 
by %PI + cells after transfection (c,d). (B) Western blot showed the knockdown of ITCH protein by siRNA 
transfection in Kelly cells (B-a) or BE2 cells (B-b). L2K = L2K only. (C) Expression of ITCH mRNA  
(C-a and C-b) and ITCH protein (C-c) on Kelly cells after transfection of 100 nM ITCH siRNA with different 
nanoparticle formulations for 4 hours (C-a) or 48 hours (C-b). ITCH protein level is measured by western blot 
48 hours after transfection (C-c).
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AT-1:ME27:ITCH siRNA-transfected group, and around 61% knockdown (33 ± 20% ITCH mRNA) of ITCH in 
GK27:ME27:ITCH siRNA-transfected group.
These data suggested that for the DOTMA/DOPE:ME27:ITCH siRNA formulation, extending the incubation 
time did not enhance the transfection efficiency; while for AT-1:ME27:ITCH siRNA and GK27:ME27:ITCH 
siRNA formulations, increasing the transfection time significantly enhanced the transfection efficiency.
Next we examined the knockdown of ITCH protein after nanoparticle transfection. Kelly cells were trans-
fected with DOTMA/DOPE:ME27:ITCH siRNA, AT-1:ME27:ITCH siRNA and GK27:ME27:ITCH siRNA for 
48 hours; cells transfected with irrelevant siRNA were used as control. Unlike the cells transfected using L2K rea-
gent, cells transfected using nanoparticles showed no difference in ITCH protein level in ITCH siRNA transfected 
samples and the irrelevant siRNA transfected samples, as indicated by western blot analysis (Fig. 3C-c).
Knockdown of ITCH upregulates TP73 in Kelly cells. As TP73 is the major protein targeted by ITCH, 
we next examined the level of TP73 protein in ITCH siRNA-transfected cells. Kelly cells were transfected with 
ITCH siRNA or irrelevant siRNA in 6-well plates using  L2K. The protein samples were collected 1 day (D1), 2 
days (D2), 3 days (D3) and 6 days (D6) after transfection. Western blot analysis with the ITCH and TP73 antibod-
ies was performed using the above samples, and the expression of each protein was normalized to β-actin (Fig. 4).
As expected, downregulation of ITCH protein was observed in samples which had been transfected with 
ITCH siRNA, in comparison to samples which were transfected with irrelevant siRNA, from 1 day to 6 days after 
transfection. However, we only detected TP73 upregulation at day 3 samples. These data suggest that downregu-
lation of ITCH by siRNA transfection could subsequently induce the stabilization of TP73 in treated cells, after 
Figure 4. Knockdown of ITCH causes the upregulation of TP73 (A) and induces apoptosis of Kelly cells upon 
irradiation. (A) Western blot showing silencing of ITCH protein and upregulation of TP73 after transfection 
of ITCH siRNA in Kelly cells. 1, 3, 5 and 7 are samples transfected with ITCH siRNA; 2, 4, 6 and 8 are samples 
transfected with irrelevant siRNA. D1, D2, D3 and D6 suggested days after transfection. (B) Apoptotic cells 
after irradiation of Kelly cells which have been transfected with ITCH siRNA (b) and irrelevant siRNA (a). 
Quantification of percentage of SubG1 cells within each treatment group (c).
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the ITCH protein has been downregulated. What is more, TP73 upregulation is transient, which could not be 
detected at 6 days after the ITCH siRNA transfection.
Knockdown of ITCH sensitizes Kelly cells to irradiation. Our hypothesis is that upon silencing of 
ITCH, the tumour suppressor protein TP73 would be stabilized which, theoretically for p53 mutant cells, would 
trigger the apoptotic pathway upon the drug/irradiation treatment. Kelly cells were transfected with ITCH and 
irrelevant siRNA, respectively. Three days later, cells were subjected to 4 Gy irradiation. The subG1 population 
was analyzed one day after the irradiation. As shown in Fig. 4B, one day after irradiation, cells which have been 
transfected with ITCH siRNA contained 8.36% apoptotic cells, while cells which have been transfected with 
irrelevant siRNA contained 3.56% SubG1 cells. This difference was statistically significant between the 2 groups 
(p < 0.001, Mann-Whitney test).
In conclusion, we have shown that silencing of ITCH by siRNA significantly induced apoptosis of Kelly neu-
roblastoma cells upon irradiation.
In vivo silencing of ITCH in neuroblastoma xenografts. The relative expression of ITCH in the xeno-
graft tumours was decreased at 48 hours after transfection, not at 24 h. As shown in Table 1, the relative expres-
sion of ITCH at 24 hours in the ITCH siRNA- treated group was similar to that in the irrelevant siRNA- treated 
group, when the data were normalized to either β-actin or SDHA37, there were no statistical differences between 
these 2 groups (Fig. 5A) by either normalization method. However, 48 hours after delivery, we found that the 
relative expression of ITCH was significantly lower in the treated group than in the control group (Fig. 5A), when 
the data were normalized to either β-actin (p = 0.0252, 19.15% silencing) or SDHA (p = 0.0426, 14.6% silencing).
Individual sample response to ITCH siRNA treatment showed that more samples in the treated group 48 hours 
after treatment express lower levels of ITCH mRNA. We then plotted all the individual samples for their relative 
expression of ITCH, in comparison to control sample. Fig. 5B shows that at 24 hours after transfection there were 
no differences in ITCH expression between the ITCH siRNA treated group and irrelevant siRNA treated group. 
However, the treated group at 48 hours after treatment showed significantly decreased levels of ITCH expression 
than the control group. The tendency was the same when the samples were normalized with either β-actin or 
SDHA (Fig. 5B).
We also compared the percentage of low-ITCH expression samples in each group. The percentage of 
low-ITCH expression samples (relative expression lower than 1 or 0.8) within each group was calculated, and the 
differences between treated and control group is shown in Fig. 6. We found that 24 hours after delivery, there were 
only slightly more or even less samples expressing lower levels of ITCH in the treated group, while at 48 hours 
after delivery, there were 27.14% or 35% more samples expressing lower levels of ITCH (relative expression <0.8) 
in the treated group than in the control group, when the data were normalized to β-actin or SDHA, respectively.
Discussion
Current therapy for neuroblastoma, involves surgery, chemotherapy, monoclonal antibody treatment, and radi-
otherapy38 with efficacy of each treatment depending on the disease stage and its biological features39. Surgery 
alone may achieve remission of MYCN-amplified neuroblastoma if it remains localized38 but usually patients 
receive 13-cis-retinotic acid treatment to induce neuronal differentiation40 and maintain a minimal residue 
disease41 although patients frequently develop 13-cis-retinotic acid resistance leading to relapse42. Anti-GD2 
antibody therapies combined with granulocyte macrophage colony stimulating factor (GM-CSF), interleukin-2 
(IL-2) and 13-cis-retinotic acid have improved the 2-year survival rate by 20%40,43,44, but neuroblastoma cells with 
low GD2 expression fail to respond to this therapy45 and so the prognosis of high-risk neuroblastoma remains 
very poor43,46 and new treatments are required. We have previously described nanoformulations for delivery of 
plasmid DNA encoding IL-2 and IL-1235,36 for therapy of murine form of neuroblastoma but here we explore a 
new approach in human p53-deficient neuroblastoma cells based on siRNA delivery to silence ITCH ligase and 
so induce p73 expression to mediate apoptosis in response to DNA damaging agents or radiation. Although this 
approach has been described elsewhere for therapy of pancreatic cancer33, we have explored its potential for the 
first time in developing a novel therapy for neuroblastoma.
Mutations of the tumour suppressor gene p53 are the major reason for recurrent, drug-resistant neuroblas-
toma5. In addition to restoring the functional p53 pathway, manipulation of alternative tumour suppressor path-
ways may provide therapeutic benefit for treatment of these types of tumours. In this study, we aimed to explore 
the possibility of elevating the TP73 protein, a homologous protein of the p53 superfamily, by inhibiting its ubiq-
uitinylation pathway, to elicit the apoptosis of p53-mutant neuroblastoma cells. The molecule we chose to target 
is ITCH, the E3 ubiquitin ligase responsible for the degradation of a panel of tumour suppressor genes, including 
TP73. In this study, we showed that ITCH and TP73 were expressed in two p53 mutant neuroblastoma cell lines, 
with Kelly cells expressing higher levels of both ITCH and TP73 than BE2 cells (Fig. 1), suggesting the existence 
Relative expression of ITCH/β-actin 
(mean ± SEM)
Relative expression of ITCH/SDHA 
(mean ± SEM)
24 hours 48 hours 24 hours 48 hours
ITCH siRNA 1.05 ± 0.06 0.76 ± 0.05 1.18 ± 0.10 0.82 ± 0.05
Irrelevant siRNA 1.10 ± 0.06 0.94 ± 0.05 1.13 ± 0.06 0.96 ± 0.04
P value p > 0.05 p = 0.0252 p > 0.05 p = 0.0426
Table 1. The relative expression of ITCH in the xenograft tumours.
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of a compensating tumour suppressor pathway in the absence of functional p53 in these cell lines, and the feasi-
bility of manipulating this pathway to induce the programmed cell death of tumour cells. ITCH, an E3 ubiqui-
tin ligase, is the key enzyme responsible for ubiquitinylation and degradation of the TP73 protein26. Therefore, 
downregulation of ITCH expression in tumour cells undoubtedly provides therapeutic value for treatment of the 
p53-mutant tumours. In our in vitro transfection experiment, although both cell types could be transfected and 
achieved silencing of ITCH at the mRNA level, BE2 cells failed to respond at the protein level (Fig. 3B). Therefore, 
we focused on Kelly cells as the in vitro and in vivo model in the following studies.
The p73 gene has two distinct promoters coding for two protein isoforms with opposite effects: the 
transactivation-proficient TAp73 shows pro-apoptotic effects and the amino-terminal-deleted DeltaNp73 has 
an anti-apoptotic function. The cellular outcome of the tumour cells upon treatment is finely regulated by the 
balance between TAp73 and DeltaNp73 in the p53-mutant cells15. It has been shown that the major isoform of 
TP73 expressed in Kelly cells was the TAp7347, whose upregulation would enhance the apoptosis of the cells upon 
treatment. Our western blot using a p73 antibody also confirmed the single TAp73 band at a molecular weight 
of around 73 KD (Fig. 4A). After ITCH silencing, the TP73 was upregulated at the protein level in Kelly cells and 
consequently these cells which were initially unresponsive, underwent apoptosis upon irradiation, as indicated 
by an increased SubG1 population (Fig. 4B). We found that downregulation of ITCH protein was observed in 
samples which had been transfected with ITCH siRNA, in comparison to samples which were transfected with 
irrelevant siRNA, from 1 day to 6 days after transfection. However, we only detected TP73 upregulation in the 
sample transfected 3 days before (Fig. 4A). This is expected as in the biological process, the TP73 protein level is 
regulated by the E3 ubiquitin ligase ITCH: in the presence of ITCH protein, TP73 is polyubiquitinated, targeting 
it for degradation. Once the ITCH protein is downregulated by siRNA silencing, the ubiquitination of TP73 is 
also inhibited, leading to accumulation of the TP73 in the cells. However, as these are sequential biology pro-
cesses, it is understandable that the decrease of ITCH and the increase of TP73 do not happen at the same time 
point; but rather occur in a stepwise manner.
We also noticed that the extent of TP73 protein upregulation was not as dramatic as that of the ITCH silenc-
ing, and the increase of the SubG1 cell population was only mild in ITCH siRNA-transfected Kelly cells compared 
to irrelevant siRNA-treated cells. This suggested that other TP73-independent mechanisms may also be involved 
in ITCH-mediated tumor cell apoptosis, because TP73 is not the sole protein regulated by ITCH. Other molecules 
Figure 5. ITCH expression in tumours 24 hours and 48 hours after ITCH siRNA treatment. (A) Relative ITCH 
expression in each treatment group. (B) Individual sample responses to the ITCH siRNA treatment at 24 hours 
or 48 hours. There were no differences between the treatment group and the control group 24 hours after 
treatment. There were, however, more samples with lower levels of ITCH expression in the treated group than 
the control group 48 hours after treatment.
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such as TP6330, large tumour suppressor 1 (LATS1)28,29,48, and RASSF5/NORE132 have also been reported to be 
negatively regulated by the ITCH protein.
In our experiments, we used nanoparticles as a carrier system to deliver the ITCH siRNA in vivo. This was 
based on our previous findings that the receptor-targeted liposome-peptide-siRNA nanoparticle is an efficient 
delivery system for ex vivo and in vivo applications49–53. The formulation of the nanoparticles contains peptide 
ME27 which can mediate receptor-specific targeting via its interaction with integrin αvβ3 and αvβ5 on cells. 
Integrin αvβ3 is a well-characterized cell adhesion molecule which is highly expressed on active angiogenic 
endothelium and glioblastoma tumor cells54, and being used as a targeting molecule for radioimmunotherapy 
of glioblastoma in vivo. We found that these integrins were present in neuroblastoma cell lines (Fig. 2), sug-
gesting that nanoparticles formulated with our experimental design could effectively target tumour sites via the 
receptor-peptide interaction after in vivo delivery into a neuroblastoma xenograft model. In addition to deter-
mining the expression of integrins in neuroblastoma cell lines, we performed in vitro transfections with nan-
oparticles where we compared the transfection efficiency of the lipid formulations which contained 1% PEG 
(AT-1), 5% PEG (GK27) and no PEG (DOTMA/DOPE). The presence of PEG has been shown to stabilize the 
nanoparticles in serum in vivo, preventing aggregation or disassembly50. We found that the lipid formulations 
containing PEG (AT-1 and GK27) did not work as well as the lipid without PEG (DOTMA/DOPE) in 4 hour 
transfections (Fig. 3C), although at longer incubation times (48 hours), ITCH siRNA silencing was evident, sug-
gesting a slow-releasing process with these nanoparticles in cell culture. This was expected as it is well known 
that PEGylation, although improving nanoparticle stability in the presence of serum proteins, can also reduce 
transfection efficiency by retarding cell membrane interactions55.
Indeed, our in vivo results showed a similar tendency of slow release of siRNA from the nanoparticle formu-
lations. 24 hours after transfection, there was no silencing detected in the treated groups, while 48 hours after 
transfection silencing was detectable by qPCR, with statistically lower levels of ITCH expression in the ITCH 
siRNA-treated group than in the irrelevant siRNA-treated group (Fig. 5A). There were also more samples express-
ing lower ITCH mRNA levels in the treated group than in the control group 48 hours after transfection (Fig. 5B). 
This result was consistent with our in vitro findings and therefore, a combination of ITCH siRNA and the chemo/
radiotherapy on xenograft models will be performed in the future to further evaluate the therapeutic effect of 
manipulating ITCH expression in the treatment of drug-resistance neuroblastoma.
This study shows for the first time the potential for a siRNA therapy in treating neuroblastoma which would 
potentially be used to enhance the efficacy of radiation therapy or other chemotherapeutic drugs designed to 
induce apoptosis. The strategy of augmenting the efficacy of conventional cancer therapies with siRNA could be 
very effective and clinically attractive.
Figure 6. Percentage of tumour samples of each treatment group which express ITCH mRNA relatively lower 
than 1, 0.9, 0.8 and 0.7, respectively.
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Methods
Ethics approval. All in vivo procedures were approved by UCL animal care policies and were carried out 
under Home Office Licenses issued in accordance with the United Kingdom Animals (Scientific Procedures) Act 
1986 (UK).
Materials. 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA), 1,2-dipalmitoyl-sn-glycero-3-p
hosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DPPE-PEG2000) and 1,2-dioleoyl-sn-glycero-3-p
hosphoethanolamine (DOPE) were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL, USA). Peptide ME27 
(K16RVRRGACRGDCLG) was synthesized by Alta Bioscience (Birmingham, UK).
Cell culture. Two p53-mutant neuroblastoma cell lines, Kelly47,56 and SK-N-BE-2 (BE2) cells5 were main-
tained in vitro in RPMI-1640 medium (Sigma, Dorset, UK) supplemented with 2 mM Glutamine and 10% FBS 
(Thermo Fisher, Paisley, UK). Cells were split every 3–4 days.
Transfection with Lipofectamine 2000 (L2K). One day before transfection, cells were plated at 8 × 104 
cells per well for 24-well plates or 1.5 × 105 cells per well for 6-well plates in culture medium. On the day of trans-
fection, L2K (Thermo Fisher, Paisley, UK) and ITCH/Irrelevant siRNA (Eurogentec, Southampton, UK) were 
pre-diluted in OptiMEM (Thermo Fisher, Paisley, UK) at various concentrations and mixed to form complexes at 
room temperature (RT) for 25 min before adding to cells. mRNAs or protein lysates were collected 72 hours after 
transfection for further analysis. For cell viability assay, transfected cells were collected 72 hours after transfection 
and stained with 1 µg/ml Propidium Iodide (PI). Percentage of PI + cells in each group was determined using 
a FACS calibur machine (BD, Wokingham, UK). Data were analyzed using the Flowjo software (Flowjo, LLC).
Transfection with nanoparticles in vitro. Nanoparticles were formulated as a mixture of 
Lipid:peptide:siRNA, as described previously52,57. In this study, we pre-formulated 3 different liposomes with 
different concentrations of PEG; 1) DOTMA/DOPE (DD), containing no PEG; 2) AT-1, DD containing 1% 
PEG; and 3) GK27, DD which contained 5% PEG. The peptide used in this study is ME27. The siRNA used is 
ITCH siRNA (Eurogentec, Southampton, UK, sense strand: 5′ GCU-GUU-GUU-UGC- CAU-AGA-A55 3′; anti-
sense strand: 5′ UUC-UAU-GGC-AAA- CAA-CAG-C55 3′) and Irrelevant siRNA (Dharmacon, UK, D-001810, 
on-target plus Non-targeting pool). The nanocomplexes were made at a Lipid:Peptide:siRNA weight ratio of 
1:4:1, and the siRNA concentration used for transfection was 100 nM. Kelly cells were seeded at 8 × 104 cells/
well in 24-well plates one day before transfection. Nanoparticles were carefully prepared and mixed in the order 
of Lipid + Peptide + siRNA, and left at RT for 30 min in order to form complexes before adding to the cells. The 
whole plate was centrifuged at 1500 rpm for 5 min to allow the nanoparticles to settle and incubated for either 
4 hours or 48 hours before analysis.
Semi-quantitative RT-PCR. RNA of cultured cells was extracted using RNeasy mini kit (Qiagen, 
Manchester, UK). RNA concentration was determined by NanoDrop 3.1 software. A one-step RT-PCR kit 
(Qiagen, Manchester, UK) was used to perform the semi-quantitative RT-PCR, using 10 ng RNA from each 
sample. The sequences of the primers are: ITCH forward: 5′-ACCGGCTGCCATCTTAGTCT-3′, ITCH 
reverse: 5′-GGAAAACCTGAAGTTCTCACAGT-3′; beta-actin forward: 5′-GCCCTGAGGCACTCTTCCA-3′, 
beta-actin reverse: 5′-ATGCCACAGGACTCCATGC-3′; SDHA forward: 5′-TGGGAACAAGAGGGCATCTG-3′, 
SDHA reverse: 5′-CCACCACTGCATCAAATTCATG-3′.
Real-time PCR. cDNA from each RNA sample was synthesized using superscript III first strand synthe-
sis kit (Thermo Fisher, Paisley, UK). To determine the ITCH expression, real time PCR was performed using 
SYBR-green qPCR kit (Eurogentec, Southampton, UK), using beta-actin or SDHA (sequence details as above) 
as endogenous control. The qPCR was run using either StepOne plus qPCR machine (Thermo Fisher, Paisley, 
UK) or CFX96 qPCR system (Bio-Rad, Watford, UK). Results were analysed using their corresponding software.
Immunostaining on cultured cells. Cells were plated on poly-lysine coated coverslips (VWR, Lutterworth, 
UK) at a density of 5 × 104 cells/ml. 24 hours later the cells were fixed with 4% PFA for 10 min at RT. After one 
hour blocking with 10% normal goat serum (Sigma Dorset, UK,), the cells were incubated with antibodies against 
ITCH (BD, Wokingham, UK, 1:100), p73 (Generon, Slough, UK, 1:500), integrin αv (R&D, Cleckheaton, UK, 
1:100), β3 (Generon, Slough, UK, 1:100) and β5 (R&D, 1:100) at 4 °C overnight, followed by one hour incubation 
with Alexa-488 or Alexa-594 conjugated corresponding secondary antibodies (1:500, Thermo Fisher, Paisley, 
UK). The coverslips were then mounted with hydromount (Sigma, Dorset, UK) mounting medium containing 
10 µg/ml DAPI and images were acquired using the Metamorph software.
Western blot. 72 hours after transfection, protein was extracted in RIPA (Radio-Immunoprecipitation Assay) 
lysis buffer (Sigma, Dorset, UK) containing a complete protease inhibitor cocktail (1:100, Roche, Welwyn Garden 
City, UK). 100 µl of lysis buffer was added to each well of the 6-well plate, and left on ice for 10 minutes. Samples 
were collected and boiled for 3 min and then centrifuged at 14,000 × g for 10 min at 4 °C. The supernatants were 
stored at −80 °C until needed. 30 µl /well of each sample were loaded onto NuPAGE Novex 10% bis-Tris Gel, and 
run at a constant voltage of 150 V for 1 hour, before being transferred to a nitrocellulose membrane at 300 mA for 
2 hours. The membrane was then blocked with Odyssey block solution (LI-COR Biosciences, Cambridge, UK) for 
60 min, incubated by primary antibodies of mouse anti-ITCH antibody (1:2000, BD, Wokingham, UK) or rabbit 
anti-TP73 (1:1000, Generon, Slough, UK), and mouse anti-beta actin (1:5000, Sigma, Dorset, UK) overnight at 
4 ºC. After washing with PBS containing 1% Tween 20 (PBST) for 15 min × 3 times at room temperature, the mem-
brane was then incubated with IRDye 680 RD goat anti-rabbit or IRDye 800CW goat anti-mouse 2ry antibodies 
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(1:15000, LI-COR Biosciences, Cambridge, UK) for 1 hour at RT. The image of the blotted membrane was acquired 
by the Odyssey Clx infrared imaging system (LI-COR Biosciences, Cambridge, UK) using image studio software. 
For quantification of the ITCH or TP73 expression, the intensity of the ITCH or TP73 protein bands was measured 
using Image Studio Lite ver 5.2, and normalized against the intensity of the corresponding beta-actin band.
For western blotting of integrins, the primary antibodies used were: goat anti-human integrin alpha V 
(1:1000, R&D, Cleckheaton, UK) or mouse anti-human integrin beta 3 (1:1000, R&D, Cleckheaton, UK) or 
Sheep anti-human integrin beta 5 (1:1000, R&D, Cleckheaton, UK) followed by the corresponding anti-goat/
sheep/mouse IRDye 680 RD donkey anti-goat/sheep and IRDye 800CW goat anti-mouse 2ry antibodies (1:15000, 
LI-COR Biosciences, Cambridge, UK) for 1 hour at RT. The membrane was then visualized using the Odyssey Clx 
infrared imaging system.
SubG1 analysis. To examine the effects of ITCH silencing on the apoptosis of neuroblastoma cells upon 
irradiation, Kelly cells were first transfected with ITCH siRNA as described above, using irrelevant siRNA as a 
control. Cells were exposed to 4 Gy irradiation three days after transfection then 24 hours after irradiation, cells 
were trypsinized and centrifuged at 500 x g, for 5 min. Pre-cold 70% ethanol was then added dropwise to the cell 
pellet, and the cells were fixed at 4 °C for 30 min before repeated centrifugation and the cell pellet was washed 
with citrate buffer (0.2 M Na2HPO4 and 0.1 M Citric acid) twice before adding 50 µl RNaseA (100 µg/ml) followed 
by 50 µg/ml propidium iodide (PI) for 5 min. The cells were then pelleted again at 500 x g for 5 min, and then 
re-suspended in 0.5 ml PBS for FACS analysis. The cell cycle profile was acquired using a FACS calibur machine 
(BD, Wokingham, UK) and the percentage of cells in the SubG1 region was calculated using the Flowjo software 
(Flowjo, LLC).
Establishment of the xenograft neuroblastoma model and in vivo transfection of ITCH siRNA 
with nanoparticles. 6–8 week old NOD-SCID gamma (NSG) female mice were ordered from Charles River 
laboratories, Harlow, UK. The mice were acclimatized for 1–2 weeks before engrafting the human neuroblas-
toma cells. On the day of engraftment, Kelly cells were harvested by trypsinisation and re-suspended in RPMI 
1640 medium at a density of 3 × 106 cells/100 µl. 100 µl cell suspension was then mixed with an equal volume of 
Matrigel (BD biosciences) on ice and immediately injected subcutaneously into the left or right upper flank of the 
mouse. The body weight and the tumour size/volume of each mouse were monitored from 4 days after engraft-
ment onwards. The in vivo administration of the ITCH siRNA nanoparticles was performed on mouse once its 
tumour grew bigger than 5 mm at both dimensions. The nanoparticle formulation for the in vivo study was also 
prepared at the 1:4:1 weight ratio, using cationic lipid AT-1, which contains 1% PEG, and the peptide used was 
ME27. 1 mg siRNA/kg was injected intravenously into each mouse. The tumours were harvested either 24 hours 
or 48 hours after administration, and processed for qPCR analysis.
Real time RT-PCR analysis of tumour samples. Each tumour was divided into 4 parts and RNA was 
extracted respectively for real time RT-PCR analysis. iTaq Universal SYBR Green One-Step Kit (Bio-rad, Watford, 
UK) was used in this assay. For normalization, 2 separate housekeeping genes, beta-actin and SDHA37 were 
included. As we had in total 104 samples to test, it was not possible to fit all samples in a single 96-well testing plate. 
Therefore, we included one sample from an untreated tumour as a common control. This sample was incorporated 
in every plate we ran and all the data from each plate were calculated relative to this sample, in other words, the 
ddCT value of each sample was calculated by subtracting the dCT value of this common control sample.
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